| P/E (FY) | — | Sales (TTM) | $653,000 |
| Earnings (TTM) | -$40.2M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | 5.75 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $56.3M | Trading Days | 785 |
| 52W High | 14.93 |
| 52W Low | 2.66 |
| % Off High | −80.24% |
| YTD | −62.94% | 1Y | −70.91% |
| 3Y | −70.44% | Since incept. (ann.) | −43.78% |
| Ann. Volatility (1Y) | 143.98% | Ann. Volatility (3Y) | 116.46% |
| Sharpe (1Y) | 0.02 | Sharpe (3Y) | 0.31 |
| Max Drawdown (1Y) | −81.41% | Max Drawdown (3Y) | −81.41% |
| Beta (3Y, vs SPY) | 1.91 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| BOLD | Boundless Bio, Inc. | $55.5M | — |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $55.1M | — |
| CNTX | Context Therapeutics Inc. | $54.3M | — |
| RANI | Rani Therapeutics Holdings, Inc. | $54.2M | — |
| ANVS | Annovis Bio, Inc. | $58.6M | — |
| PMVP | PMV Pharmaceuticals, Inc. | $58.7M | — |
| XLO | Xilio Therapeutics, Inc. | $52.9M | — |
| CING | Cingulate Inc. | $60.1M | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $52.7M | — |
| DWTX | Dogwood Therapeutics, Inc. | $52.1M | — |
| RFL | Rafael Holdings, Inc. |
| $61.8M |
| — |
| CTOR | CITIUS ONCOLOGY, INC. | $50.3M | — |
